Trial Profile
Prospective Double-blind Randomized Study to Evaluate Lucentis for Prophylaxis Against the Conversion to Neovascular Age-related Macular Degeneration (AMD) in High-risk Eyes (Let's ProTECT AMD Eyes)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Sep 2018
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms PROTECT
- 27 Aug 2018 Status changed from active, no longer recruiting to completed.
- 18 Oct 2016 Planned number of patients changed from 88 to 4.
- 18 Oct 2016 Planned End Date changed from 1 Nov 2017 to 1 Jul 2017.